PharmaSGP Holding SE strengthens the Management Board to further accelerate
growth

EQS-News: PharmaSGP Holding SE / Key word(s): Personnel
PharmaSGP Holding SE strengthens the Management Board to further accelerate
growth

21.06.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PharmaSGP Holding SE strengthens the Management Board to further accelerate
growth

  * PharmaSGP expands the Management Board as of July 1, 2024 with Peter
    Gerckens as Chief Commercial Officer (CCO), a newly created position

  * Peter Gerckens will be responsible for international markets, sales and
    new businesses

Gräfelfing, June 21, 2024 - German OTC pharmaceutical company PharmaSGP
Holding SE is expanding its existing management team with Peter Gerckens as
Chief Commercial Officer (CCO) as of July 1, 2024. With the newly created
CCO position, PharmaSGP is bringing additional management expertise into the
company and thus further strengthens the foundation for the continuation of
the profitable growth course in the coming years.

Peter Gerckens (37) started his career in 2012 at Procter & Gamble in the
marketing department and moved to McKinsey's Munich office in 2013. There he
advised clients on strategic and operational issues for over eight years,
including in the consumer goods industry. Before joining PharmaSGP, Mr.
Gerckens was Managing Director of a market-leading, medium-sized media
company in Munich with more than 100 employees. His responsibilities there
included finance, marketing and several business units. In his role as CCO
at PharmaSGP, Mr. Gerckens will be responsible for the expansion of
international markets, sales and new businesses.

Peter Gerckens is a business economist and holds a Bachelor's degree (B.A.)
from the University of St. Gallen, a Master's degree (M.Sc.) from the London
School of Economics and an MBA from Harvard Business School.

Natalie Weigand, CEO of PharmaSGP: 'PharmaSGP has been pursuing a successful
growth strategy for years and was able to generate revenues of more than
EUR100 million for the first time in 2023 with a continued attractive adjusted
EBITDA margin of over 30%. In order to further increase our market share in
the dynamically growing healthcare and pharmaceutical market, we are now
strengthening our management team with a Chief Commercial Officer. In Peter
Gerckens, we have gained an experienced manager with strong implementation
skills for this position and we are convinced that he will make a decisive
contribution to achieving our ambitious growth targets.'


Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=96bc5ee46df4620f856776eea1f0b8b9
Image title: Peter Gerckens

Peter Gerckens


CONTACT

cometis AG
Claudius Krause
Phone: +49-611-20585528
Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio
of over-the-counter (OTC) pharmaceuticals and other healthcare products that
are marketed with a focus on the pharmacy distribution channel. These
products are mostly based on natural active pharmaceutical ingredients with
documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic
pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is
the market leader for systemic chemical-free pain remedies with its brand
families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain.
Furthermore, PharmaSGP also offers leading products against sexual weakness
and vertigo symptoms. Since introducing the first product from the current
product portfolio in 2012, PharmaSGP has successfully established its
business model in other European countries, including Austria, Italy,
Belgium, Spain and France. In September 2021, the product portfolio was
expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus
also strengthening or developing the indications pain and sleep disorder.
The sales territory was expanded to include Switzerland and Eastern Europe.
In 2023, PharmaSGP generated revenues of EUR101.1 million at an adjusted
EBITDA margin of 33.7%.

In order to further expand its competitive position, PharmaSGP plans to
increase the number of indications covered by PharmaSGP's product offering,
increase PharmaSGP's European footprint, and accelerate its growth strategy
especially by capitalizing on selected M&A opportunities.


---------------------------------------------------------------------------

21.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        PharmaSGP Holding SE
                   Lochhamer Schlag 1
                   82166 Gräfelfing
                   Germany
   E-mail:         ir@pharmasgp.com
   Internet:       https://pharmasgp.com
   ISIN:           DE000A2P4LJ5
   WKN:            A2P4LJ
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Munich, Tradegate Exchange
   EQS News ID:    1930049

End of News EQS News Service
---------------------------------------------------------------------------

1930049 21.06.2024 CET/CEST